The genetics of common kidney disease: A pathway toward clinical relevance

Nature Reviews Nephrology

Volumn 7, Issue 8, 2011, Pages 458-468

  Drawz, Paul E ^a   Sedor, John R ^a  

^a Center for the Study of Kidney Disease and Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SCREENING; HERITABILITY; HUMAN; HYPERTENSION; KIDNEY FAILURE; LINKAGE ANALYSIS; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

APOLIPOPROTEINS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, HDL; MODELS, GENETIC; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; PHARMACOGENETICS; RISK ASSESSMENT;

EID: 79961020838     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.85     Document Type: Review

References (108)

1. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1-22 (2003). (Pubitemid 36503465)
2. Pattaro, C. et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 76, 297-306 (2009).
3. Fox, C. S. et al. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: The Framingham Heart Study. J. Am. Soc. Nephrol. 15, 2457-2461 (2004). (Pubitemid 39159346)
4. Chen, G. et al. A genome-wide search for linkage to renal function phenotypes in West Africans with type 2 diabetes. Am. J. Kidney Dis. 49, 394-400 (2007).
5. Kao, W. H. et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat. Genet. 40, 1185-1192 (2008).
6. Freedman, B. I. et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 75, 736-745 (2009).
7. Freedman, B. I. et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN study. Am. J. Nephrol. 29, 626-632 (2009).
8. Kopp, J. B. et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 40, 1175-1184 (2008).
9. Salkin, A. When in doubt, spit it out. NYTimes.com [online], http://www.nytimes.com/2008/09/14/fashion/14spit.html (2008).
10. Pollack, A. Start-up may sell genetic tests in stores. NYTimes.com [online], http://www.nytimes.com/2010/05/11/health/11gene.html (2010).
11. O'Seaghdha, C. M. & Fox, C. S. Genetics of chronic kidney disease. Nephron Clin. Pract. 118, c55-c63 (2011).
12. Iyengar, S. K., Freedman, B. I. & Sedor, J. R. Mining the genome for susceptibility to diabetic nephropathy: The role of large-scale studies and consortia. Semin. Nephrol. 27, 208-222 (2007). (Pubitemid 46550309)
13. Rich, S. S. Genetics of diabetes and its complications. J. Am. Soc. Nephrol. 17, 353-360 (2006).
14. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881-888 (2008).
15. Köttgen, A. et al. New loci associated with kidney function and chronic kidney disease. Nat. Genet. 42, 376-384 (2010).
16. Freedman, B. I. Genetic factors in common complex renal and cardiovascular diseases. Adv. Chronic Kidney Dis. 13, 105-109 (2006).
17. Ng, D. P. & Krolewski, A. S. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr. Mol. Med. 5, 509-525 (2005). (Pubitemid 41086776)
18. Khera, A. V. & Rader, D. J. Discovery and validation of new molecular targets in treating dyslipidemia: The role of human genetics. Trends Cardiovasc. Med. 19, 195-201 (2009).
19. Lifton, R. P. Individual genomes on the horizon. N. Engl. J. Med. 362, 1235-1236 (2010).
20. National Human Genome Research Institute. A Catalog of Published Genome-Wide Association Studies [online], http://www.genome.gov/gwastudies (2011).
21. Edwards, A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424 (2005). (Pubitemid 40530082)
22. Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005). (Pubitemid 40530081)
23. Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005). (Pubitemid 40530070)
24. Hirschhorn, J. N. Genomewide association studies-illuminating biologic pathways. N. Engl. J. Med. 360, 1699-1701 (2009).
25. Köttgen, A. Genome-wide association studies in nephrology research. Am. J. Kidney Dis. 56, 743-758 (2010).
26. Goldstein, D. B. Common genetic variation and human traits. N. Engl. J. Med. 360, 1696-1698 (2009).
27. McClellan, J. & King, M. C. Genetic heterogeneity in human disease. Cell 141, 210-217 (2010).
28. Levy, D. et al. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41, 677-687 (2009).
29. Newton-Cheh, C. et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41, 666-676 (2009).
30. Ji, W. et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40, 592-599 (2008). (Pubitemid 351601207)
31. Köttgen, A. et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 41, 712-717 (2009).
32. Sedor, J. R. Uromodulin and translational medicine: Will the SNPs bring zip to clinical practice? J. Am. Soc. Nephrol. 21, 204-206 (2010).
33. Chambers, J. C. et al. Genetic loci influencing kidney function and chronic kidney disease. Nat. Genet. 42, 373-375 (2010).
34. Pezzolesi, M. G. et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58, 1403-1410 (2009).
35. Hanson, R. L. et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 56, 975-983 (2007). (Pubitemid 46525073)
36. Millis, M. P., Bowen, D., Kingsley, C., Watanabe, R. M. & Wolford, J. K. Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. Diabetes 56, 3027-3032 (2007). (Pubitemid 350223639)
37. Shimazaki, A. et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes 54, 1171-1178 (2005). (Pubitemid 40446333)
38. Pezzolesi, M. G. et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes 58, 2698-2702 (2009).
39. Leak, T. S. et al. Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann. Hum. Genet. 73, 152-159 (2009).
40. Hanson, R. L. et al. ELMO1 variants and susceptibility to diabetic nephropathy in American Indians. Mol. Genet. Metab. 101, 383-390 (2010).
41. McKusick, V. A. Genetics and the nature of essential hypertension. Circulation 22, 857-863 (1960).
42. Levy, D. et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension 36, 477-483 (2000).
43. Adeyemo, A. et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 5, e1000564 (2009).
44. Takeuchi, F. et al. Blood pressure and hypertension are associated with 7 loci in the Japanese population. Circulation 121, 2302-2309 (2010).
45. Lifton, R. P., Gharavi, A. G. & Geller, D. S. Molecular mechanisms of human hypertension. Cell 104, 545-556 (2001). (Pubitemid 32201949)
46. Bostrom, M. A. & Freedman, B. I. The spectrum of MYH9-associated nephropathy. Clin. J. Am. Soc. Nephrol. 5, 1107-1113 (2010).
47. Freedman, B. I. & Sedor, J. R. Hypertension-associated kidney disease: Perhaps no more. J. Am. Soc. Nephrol. 19, 2047-2051 (2008).
48. Arrondel, C. et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J. Am. Soc. Nephrol. 13, 65-74 (2002). (Pubitemid 34042012)
49. Seri, M. et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat. Genet. 26, 103-105 (2000).
50. Nelson, G. W. et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum. Mol. Genet. 19, 1805-1815 (2010).
51. Genovese, G. et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
52. Freedman, B. I. et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21, 1422-1426 (2010).
53. Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345-350 (2010).
54. Genovese, G. et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 78, 698-704 (2010).
55. Freedman, B. I. et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21, 1422-1426 (2010).
56. Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transplant. 11, 1025-1030 (2011).
57. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
58. Gibson, G. Hints of hidden heritability in GWAS. Nat. Genet. 42, 558-560 (2010).
59. Yang, J. et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565-569 (2010).
60. Purcell, S. M. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
61. Maher, B. Personal genomes: The case of the missing heritability. Nature 456, 18-21 (2008).
62. Nadeau, J. H. Transgenerational genetic effects on phenotypic variation and disease risk. Hum. Mol. Genet. 18, R202-R110 (2009).
63. Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11, 446-450 (2010).
64. Manolio, T. A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166-176 (2010).
65. Kraft, P. & Hunter, D. J. Genetic risk prediction-are we there yet? N. Engl. J. Med. 360, 1701-1703 (2009).
66. Ware, J. H. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 355, 2615-2617 (2006). (Pubitemid 44969120)
67. Kathiresan, S. et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358, 1240-1249 (2008). (Pubitemid 351439225)
68. Illingworth, D. R. et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch. Intern. Med. 154, 1586-1595 (1994). (Pubitemid 24242345)
69. Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D. B. Rare variants create synthetic genome-wide associations. PLoS Biol. 8, e1000294 (2010).
70. Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT [online]. http://oba.od.nih.gov/oba/sacgt/reports/oversight-report.pdf (2000).
71. van Hoek, M. et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: A population-based study. Diabetes 57, 3122-3128 (2008).
72. Lango, H. et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 57, 3129-3135 (2008).
73. Lyssenko, V. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359, 2220-2232 (2008).
74. Talmud, P. J. et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 340, b4838 (2010).
75. Cook, N. R. & Ridker, P. M. Advances in measuring the effect of individual predictors of cardiovascular risk: The role of reclassification measures. Ann. Intern. Med. 150, 795-802 (2009).
76. Pencina, M. J., D'Agostino, R. B. Sr, D'Agostino, R. B. Jr. & Vasan, R. S. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat. Med. 27, 157-172 (2008). (Pubitemid 351193639)
77. Bang, H. et al. Screening for Occult Renal Disease (SCORED): A simple prediction model for chronic kidney disease. Arch. Intern. Med. 167, 374-381 (2007). (Pubitemid 46333938)
78. Kshirsagar, A. V. et al. A simple algorithm to predict incident kidney disease. Arch. Intern. Med. 168, 2466-2473 (2008).
79. Johnson, E. S., Thorp, M. L., Platt, R. W. & Smith, D. H. Predicting the risk of dialysis and transplant among patients with CKD: A retrospective cohort study. Am. J. Kidney Dis. 52, 653-660 (2008).
80. Keane, W. F. et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: The RENAAL study. Clin. J. Am. Soc. Nephrol. 1, 761-767 (2006).
81. Chien, K. L. et al. A prediction model for the risk of incident chronic kidney disease. Am. J. Med. 123, 836-846 e2 (2010).
82. Hippisley-Cox, J. & Coupland, C. Predicting the risk of chronic kidney disease in men and women in England and Wales: Prospective derivation and external validation of the Q Kidney Scores. BMC Fam. Pract. 11, 49 (2010).
83. Tangri, N. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305, 1553-1559 (2011).
84. Florez, J. C. et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241-250 (2006). (Pubitemid 44079339)
85. Pearson, E. R. et al. Variation in data from pharmacogenomic studies might identify gene variants that can be utilized in targeted drug therapy influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 56, 2178-2182 (2007).
86. Wright, J. T. Jr. et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293, 1595-1608 (2005). (Pubitemid 40471790)
87. Hingorani, A. D. et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 13, 1602-1609 (1995). (Pubitemid 26015783)
88. Hajjar, I. et al. Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors' effect on cognitive function: The health, aging and body composition study. J. Am. Geriatr. Soc. 58, 1035-1042 (2010).
89. Arnett, D. K. et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111, 3374-3383 (2005). (Pubitemid 40923390)
90. Lynch, A. I. et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 299, 296-307 (2008). (Pubitemid 351159366)
91. Lifton, R. P. Individual genomes on the horizon. N. Engl. J. Med. 362, 1235-1236 (2010).
92. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 78-81 (2009).
93. Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272-276 (2009).
94. Fahmi, S., Yang, C., Esmail, S., Hobbs, H. H. & Cohen, J. C. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 17, 2101-2107 (2008). (Pubitemid 351911979)
95. Lupski, J. R. et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N. Engl. J. Med. 362, 1181-1191 (2010).
96. Ashley, E. A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
97. Heshka, J. T., Palleschi, C., Howley, H., Wilson, B. & Wells, P. S. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet. Med. 10, 19-32 (2008).
98. Annes, J. P., Giovanni, M. A. & Murray, M. F. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. 363, 1100-1101 (2010).
99. Evans, J. P., Dale, D. C. & Fomous, C. Preparing for a consumer-driven genomic age. N. Engl. J. Med. 363, 1099-1103 (2010).
100. Ng, P. C., Murray, S. S., Levy, S. & Venter, J. C. An agenda for personalized medicine. Nature 461, 724-726 (2009).
101. Greene, C. N., Keong, L. M., Cordovado, S. K. & Mueller, P. W. Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. Hum. Genet. 124, 255-262 (2008).
102. Craig, D. W., Millis, M. P. & DiStefano, J. K. Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to type 1 diabetes. Diabet. Med. 26, 1090-1098 (2009).
103. Tanaka, N. et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 52, 2848-2853 (2003). (Pubitemid 37339716)
104. Köttgen, A. et al. Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies. BMC Med. Genet. 9, 49 (2008).
105. Köttgen, A. et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 41, 712-717 (2009).
106. Ng, D. P. et al. Genetic variation at the SLC12A3 locus is unlikely to explain risk for advanced diabetic nephropathy in Caucasians with type 2 diabetes. Nephrol. Dial. Transplant. 23, 2260-2264 (2008). (Pubitemid 351957589)
107. Köttgen, A. Genome-wide association studies in nephrology research. Am. J. Kidney Dis. 56, 743-758 (2010).
108. Fox, C. S. et al. A multi-marker approach to predict incident CKD and microalbuminuria. J. Am. Soc. Nephrol. 21, 2143-2149 (2010).